Next Article in Journal
The Crystal Structures of Some Bromo-Derivatives of the DPPH Stable Free Radical
Previous Article in Journal
2,3-Dihydrobenzo[e][1,3]oxazin-4-one
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Synthesis of Novel Sulfonamide Derivatives Featuring 1-(Methylsulfonyl)-4-(2,3,4-Trimethoxybenzyl)Piperazine Core Structures

1
Department of Organic Chemistry, Faculty of Chemistry, University of Plovdiv, 24 Tsar Assen Str., 4000 Plovdiv, Bulgaria
2
Department of Pharmacognosy, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria
*
Author to whom correspondence should be addressed.
Molbank 2024, 2024(3), M1879; https://doi.org/10.3390/M1879
Submission received: 12 August 2024 / Revised: 30 August 2024 / Accepted: 5 September 2024 / Published: 9 September 2024
(This article belongs to the Section Organic Synthesis)

Abstract

:
Herein we report the synthesis of three novel sulfonamide derivatives of trimetazidine—medication primarily used to treat angina pectoris. The new compounds have been fully characterized with their melting point, 1H- and 13C-NMR, UV, and mass spectrometry. The collected data confirm the successful synthesis and structural integrity of the new molecules.

1. Introduction

1-(2,3,4-Trimethoxybenzyl)-piperazine dihydrochloride (Figure 1), also known as trimetazidine dihydrochloride, is a safe and effective cellular anti-ischemic agent. This compound is a lipophilic weak base with low solubility in aqueous solutions. Trimetazidine is available on the market as a slightly hygroscopic white or off-white crystalline powder.
Trimetazidine therapy has been shown to have vasodilatory effects in individuals with heart disease, heart failure, and coronary artery conditions. Its beneficial effects may also extend to other ischemic organs, potentially through mechanisms such as reducing reactive oxygen species, altering cellular lipid composition, and inhibiting mitochondrial fatty acid oxidation [1].
Medications that promote carbohydrate oxidation also facilitate the oxidation of cardiac fatty acids, which, in the event of ischemia, reduces lactate production and elevates cellular pH. Trimetazidine, the first approved drug in this class, selectively inhibits 3-keto-acyl-CoA dehydrogenase, an enzyme involved in fatty acid β-oxidation, without impacting hemodynamics. For patients who do not respond to conventional therapy, trimetazidine is an excellent alternative to typical hemodynamic agents for relieving angina symptoms [2]. Furthermore, trimetazidine prevents oxidative damage to the mitochondrial membrane, which regulates metabolism in conditions such as ischemic heart disease, renal impairment, hepatic ischemia, and gastrointestinal disorders. In addition to its antinociceptive and potentially antidepressant properties, trimetazidine exhibits neuroprotective effects following cerebral injury. It reduces brain inflammation caused by lipopolysaccharides, promotes axonal regeneration, and protects against drug-induced oxidative damage to the hippocampus and experimental brain atrophy. In vivo experiments have shown that trimetazidine enhances brain glucose uptake and protects against cerebral ischemia–reperfusion injury [3].
Along with its positive properties, there are several factors that lead to limitations in its prescription. The European Medicines Agency has recommended that doctors restrict the use of trimetazidine-containing medications for treating angina pectoris. The drug should not be prescribed to patients with tinnitus, vertigo, or vision disturbances. Instead, it is advised as an add-on therapy for patients with stable angina pectoris who cannot tolerate first-line antianginal treatments. The agency also noted that a risk of movement disorders such as Parkinsonian symptoms, restless leg syndrome, tremors, and gait instability are associated with trimetazidine. The committee suggested implementing new contraindications and warnings to address the potential risks of these movement disorders [4].
Also, athletes have extended trimetazidine use into sports, employing it as a performance-enhancing substance. The drug’s capacity to boost endurance and delay fatigue made it appealing to competitors seeking an advantage. Because of these effects, trimetazidine has been classified as a metabolic modulator [1,5,6]. Recognizing the potential for misuse in sports, the World Anti-Doping Agency (WADA) added trimetazidine to its list of banned substances, effective 1 January 2014. Athletes caught using trimetazidine face penalties, including suspension and disqualification from competitions, as its use violates the principles of fair play and sports integrity. This ban highlights ongoing efforts to ensure a level playing field and safeguard the health and safety of athletes [7].
Sulfonamides, also known as sulfanilamides, represent a significant class of synthetic antimicrobial agents developed in the early 20th century. Their primary mechanism of action involves the inhibition of bacterial folic acid synthesis by acting as competitive antagonists of p-aminobenzoic acid (PABA), which is crucial for DNA production in bacteria. This action is mediated through their structural similarity to PABA, allowing sulfonamides to inhibit the enzyme dihydropteroate synthetase and ultimately leading to bacteriostatic effects rather than bactericidal ones [8].
Sulfonamides are characterized by their broad-spectrum antibacterial properties which are effective against various gram-positive and certain gram-negative bacteria, including Escherichia coli, Klebsiella, and Salmonella [9,10,11,12]. They are employed in the treatment of a range of infections, such as tonsillitis, urinary tract infections, and meningococcal meningitis [13,14]. Additionally, they exhibit activity against some fungi and protozoa, making them versatile in treating diverse infectious diseases [15,16].
The synthesis of hybrid molecules combining trimetazidine and sulfonamides represents a promising advancement in pharmaceutical development. Trimetazidine offers anti-ischemic, neuroprotective, and vasodilatory benefits, while sulfonamides provide broad-spectrum antibacterial action by inhibiting bacterial folic acid synthesis. Combining these drugs could enhance therapeutic outcomes by addressing both ischemic and infectious components of disease, potentially offering a multifaceted treatment approach. Hybrid molecules may also overcome the limitations and side effects of each individual drug, provide novel mechanisms of action, and broaden therapeutic applications [17]. This innovative strategy could improve the management of complex conditions involving ischemia and infections, potentially reducing the need for multiple medications and enhancing overall treatment efficacy.

2. Results and Discussion

We reported the successful synthesis of the following compounds: 1-(methylsulfonyl)-4-(2,3,4-trimethoxybenzyl)piperazine (3a), 1-(phenylsulfonyl)-4-(2,3,4-trimethoxybenzyl)piperazine (3b), and 1-(benzylsulfonyl)-4-(2,3,4-trimethoxybenzyl)piperazine (3c), as outlined in Scheme 1. These hybrid molecules were synthesized using a quick and efficient method described in the Materials and Methods section.
To achieve this, the corresponding sulfonyl chloride 2a–c (1 mmol) was added to a solution of trimetazidine 1 (1 mmol) in dichloromethane. The reaction mixture was stirred for ten minutes, then an excess of trimethylamine (1.5 mmol) was carefully added. After 30 min, TLC analysis confirmed the formation of the final products 3a–c. The structures of the three newly synthesized hybrid molecules were unequivocally confirmed using a comprehensive array of instrumental techniques. 1H- and 13C NMR spectroscopy provided detailed information on the chemical shifts and connectivity of the hydrogen and carbon atoms, respectively (Figures S1–S6). UV spectroscopy offered insights into the to electronic transitions and absorbance characteristics of the molecules (Figures S7–S9). Mass spectrometry, with its high-resolution capabilities, further verified the molecular weights and composition of the compounds (Figures S10–S12). Collectively, these techniques conclusively established the identities and structures of the obtained molecules.

3. Materials and Methods

All reagents and chemicals were obtained from commercial sources (Sigma-Aldrich S.A., Wien, Austria and Riedel-de Haën, Sofia, Bulgaria) and used as received without further purification. NMR spectral data were recorded on a Bruker Avance Neo 400 spectrometer (BAS-IOCCP—Sofia, Bruker, Billerica, MA, USA) operating at 400 MHz for 1H NMR and 101 MHz for 13C NMR. Spectra were acquired in DMSO-d6, with chemical shifts referenced relative to tetramethylsilane (TMS) (δ = 0.00 ppm) and coupling constants reported in Hz. NMR measurements were performed at room temperature (approximately 295 K). Melting points were determined using a Boetius hot stage apparatus and were reported uncorrected. Absorbance measurements were conducted with a Camspec M508 spectrophotometer (Spectronic CamSpec Ltd., Leeds, UK). Mass spectrometry was performed using a Q Exactive Plus high-resolution mass spectrometer (HRMS) with a heated electrospray ionization source (HESI-II) from Thermo Fisher Scientific, Inc., Bremen, Germany, and coupled with a Dionex Ultimate 3000RSLC ultrahigh-performance liquid chromatography (UHPLC) system (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Thin-layer chromatography (TLC) was carried out on 0.2 mm Fluka silica gel 60 plates (Merck KGaA, Darmstadt, Germany).

Synthetic Procedure

A solution of trimetazidine 1 (1 mmol, 0.266 g) in dichloromethane (30 mL) was prepared, to which an equivalent amount of the corresponding sulfonyl chloride 2a–c (1 mmol) was added. After 10 min, triethylamine (1.2 mmol, 0.121 g) was introduced into the solution. Following a 30 min reaction period, the solution was sequentially washed with diluted hydrochloric acid, a saturated solution of Na2CO3, and brine. The combined organic layers were then dried over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. No additional purification steps were carried out. The reagents were combined and allowed to react at room temperature.
1-(Methylsulfonyl)-4-(2,3,4-trimethoxybenzyl)piperazine 3a: white solid (m.p. 125–127 °C), Rf = 0.4 (CH2Cl2:MeOH = 1:0.02 v/v), yield 93% (0.321 g), 1H NMR (400 MHz, DMSO) δ 6.98 (d, J = 8.5 Hz, 1H), 6.77 (d, J = 8.6 Hz, 1H), 3.78 (s, 6H), 3.74 (s, 3H), 3.33 (s, 2H), 3.09 (t, J = 4.9 Hz, 4H), 2.86 (s, 3H), 2.46 (t, J = 5.0 Hz, 4H). 13C NMR (101 MHz, DMSO) δ 153.08, 152.52, 142.34, 125.18, 123.78, 108.04, 61.44, 60.75, 56.24, 55.93, 52.23, 46.01, 34.08. UV λmax, MeOH: 204 (ε = 102,000) nm, 226sh (ε = 32,600) nm. HRMS Electrospray ionization (ESI) m/z calculated for [M+H]+ C15H25N2O5S+ = 345.1479, found 345.1474 (mass error ∆m = −1.45 ppm).
1-(Phenylsulfonyl)-4-(2,3,4-trimethoxybenzyl)piperazine 3b: pale yellow oil, Rf = 0.5 (CH2Cl2:MeOH = 1:0.02 v/v), yield 95% (0.387 g), 1H NMR (400 MHz, DMSO) δ 7.78–7.70 (m, 3H), 7.70–7.61 (m, 2H), 6.89 (d, J = 8.5 Hz, 1H), 6.72 (d, J = 8.6 Hz, 1H), 3.75 (s, 3H), 3.71 (d, J = 3.4 Hz, 6H), 3.34 (s, 2H), 2.88 (s, 4H), 2.43 (s, 4H). 13C NMR (101 MHz, DMSO) δ 153.02, 152.40, 142.23, 135.31, 133.72, 129.86, 128.05, 128.00, 125.08, 123.52, 108.03, 61.34, 60.73, 56.22, 55.66, 51.87, 46.46. UV λmax, MeOH: 204 (ε = 110,000) nm, 225sh (ε = 49,000) nm. HRMS Electrospray ionization (ESI) m/z calculated for [M+H]+ C20H27N2O5S+ = 407.1636, found 407.1628 (mass error ∆m = −1.96 ppm).
1-(Benzylsulfonyl)-4-(2,3,4-trimethoxybenzyl)piperazine 3c: white solid (m.p. 93–95 °C), Rf = 0.32 (CH2Cl2:MeOH = 1:0.02 v/v), yield 87% (0.368 g), 1H NMR (400 MHz, DMSO) δ 7.46–7.31 (m, 5H), 6.96 (d, J = 8.5 Hz, 1H), 6.77 (d, J = 8.6 Hz, 1H), 4.41 (s, 2H), 3.78 (d, J = 3.3 Hz, 6H), 3.75 (s, 3H), 3.41 (s, 2H), 3.10 (t, J = 4.4 Hz, 4H), 2.38 (s, 4H). 13C NMR (101 MHz, DMSO) δ 153.10, 152.53, 142.33, 131.38, 129.91, 128.80, 128.63, 125.24, 123.69, 108.02, 61.43, 60.75, 56.24, 55.98, 54.61, 52.50, 46.01. UV λmax, MeOH: 204 (ε = 85,000) nm. HRMS Electrospray ionization (ESI) m/z calculated for [M+H]+ C21H29N2O5S+ = 421.1792, found 421.1785 (mass error ∆m = −1.66 ppm).

Supplementary Materials

Figure S1: 1H-NMR spectrum of compound 3a; Figure S2: 1H-NMR spectrum of compound 3b; Figure S3: 1H-NMR spectrum of compound 3c; Figure S4: 13C-NMR spectrum of compound 3a; Figure S5: 13C-NMR spectrum of compound 3b; Figure S6: 13C-NMR spectrum of compound 3c; Figure S7: UV spectrum of compound 3a; Figure S8: UV spectrum of compound 3b; Figure S9: UV spectrum of compound 3c; Figure S10: ESI-HRMS of compound 3a; Figure S11: ESI-HRMS of compound 3b; Figure S12: ESI-HRMS of compound 3c.

Author Contributions

Conceptualization, I.I.; methodology, S.M.; software, S.M. and D.B.; validation, I.I., S.M. and D.B.; formal analysis, D.D., S.M., D.B. and P.N.; investigation, S.M.; resources, I.I.; data curation, I.I.; writing—original draft preparation, S.M.; writing—review and editing, S.M., D.B. and I.I.; visualization, S.M.; supervision, I.I.; project administration, S.M. and I.I.; funding acquisition, I.I and S.M. All authors have read and agreed to the published version of the manuscript.

Funding

The study was conducted at the University of Plovdiv, Bulgaria and was supported by the European Union’s Next Generation EU program through the National Recovery and Resilience Plan of the Republic of Bulgaria, under project DUECOS BG-RRP-2.004-0001-C01.

Data Availability Statement

The data presented in this study are available in this article and supporting Supplementary Materials.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Onay-Besikci, A.; Ozkan, S. Trimetazidine revisited: A comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine. Cardiovasc. Ther. 2008, 26, 147–165. [Google Scholar] [CrossRef] [PubMed]
  2. Stanley, W.; Marzilli, M. Metabolic therapy in the treatment of ischaemic heart disease: The pharmacology of trimetazidine. Fundam. Clin. Pharmacol. 2003, 17, 133–145. [Google Scholar] [CrossRef] [PubMed]
  3. Al-Kuraishy, H.; Al-Gareeb, A. Central Beneficial Effects of Trimetazidine on Psychomotor Performance in Normal Healthy Volunteers. Adv. Biomed. Res. 2017, 6, 6–69. [Google Scholar] [CrossRef] [PubMed]
  4. European Medicines Agency. European Medicines Agency Recommends Restricting Use of Trimetazidine-Containing Medicines Reference Number: EMA/CHMP/417861/2012 European Medicines Agency Recommends Restricting Use of Trimetazidine-Containing Medicines (europa.eu). Available online: https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-restricting-use-trimetazidine-containing-medicines (accessed on 24 July 2024).
  5. Zhang, W.; You, B.; Qi, D.; Qui, L.; Ripley-Gonzalez, J.; Zheng, F.; Fu, S.; Li, C.; Dun, Y.; Liu, S. Trimetazidine and Exercise provide comparable improvements to high fat diet-induced muscle dysfunction through enhancement of mitochondrial quality control. Sci. Rep. 2021, 11, 19116. [Google Scholar] [CrossRef] [PubMed]
  6. Ovung, A.; Bhattacharyya, A. Sulfonamide drugs: Structure, antibacterial property, toxicity, and biophysical interactions. Biophys. Rev. 2021, 13, 259–272. [Google Scholar] [CrossRef] [PubMed]
  7. Pușcaș, A.; Ștefănescu, R.; Vari, C.-E.; Ősz, B.-E.; Filip, C.; Bitzan, J.K.; Buț, M.-G.; Tero-Vescan, A. Biochemical Aspects That Lead to Abusive Use of Trimetazidine in Performance Athletes: A Mini-Review. Int. J. Mol. Sci. 2024, 25, 1605. [Google Scholar] [CrossRef] [PubMed]
  8. Sigmund, G.; Koch, A.; Orlovius, A.-K.; Guddat, S.; Thomas, A.; Schänzer, W.; Thevis, M. Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches. Drug Test. Anal. 2014, 6, 1197–1205. [Google Scholar] [CrossRef] [PubMed]
  9. Igwe, C.N.; Okoro, U.C. Synthesis, Characterization, and Evaluation for Antibacterial and Antifungal Activities of N-Heteroaryl Substituted Benzene Sulphonamides. Org. Chem. Int. 2014, 2014, 419518. [Google Scholar] [CrossRef]
  10. Yousef, F.; Mansour, O.; Herbali, J. Sulfonamides: Historical discovery development (Structure-activity relationship notes). In-vitro In-Vivo In-Silico J. 2018, 1, 1–15. [Google Scholar]
  11. Zawodniak, A.; Lochmatter, P.; Beeler, A.; Pichler, W. Cross-Reactivity in Drug Hypersensitivity Reactions to Sulfasalazine and Sulfamethoxazole. Int. Arch. Allergy Immunol. 2010, 153, 152–156. [Google Scholar] [CrossRef] [PubMed]
  12. Ueda, Y.; Miyazaki, M.; Mashima, K.; Takagi, S.; Hara, S.; Kamimura, H.; Jimi, S. The Effects of Silver Sulfadiazine on Methicillin-Resistant Staphylococcus aureus Biofilms. Microorganisms 2020, 8, 1551. [Google Scholar] [CrossRef] [PubMed]
  13. Seneca, H. Long-Acting Sulfonamides in Urinary Tract Infections. JAMA 1966, 198, 975–980. [Google Scholar] [CrossRef]
  14. Wiedemann, B.; Heisig, A.; Heisig, P. Uncomplicated Urinary Tract Infections and Antibiotic Resistance—Epidemiological and Mechanistic Aspects. Antibiotics 2014, 3, 341–352. [Google Scholar] [CrossRef] [PubMed]
  15. Chio, L.-C.; Bolyard, L.; Nasr, M.; Queener, S. Identification of a Class of Sulfonamides Highly Active against Dihydropteroate Synthase from Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium. Antimicrob. Agents Chemother. 1996, 40, 727–733. [Google Scholar] [CrossRef] [PubMed]
  16. McFarland, M.; Zach, S.; Wang, X.; Potluri, L.-P.; Neville, A.; Vennerstrom, J.; Davis, P. Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity. Antimicrob. Agents Chemother. 2016, 60, 7017–7034. [Google Scholar] [CrossRef] [PubMed]
  17. Alkhzem, A.; Woodman, T.; Blagbrough, I. Design and synthesis of hybrid compounds as novel drugs and medicines. RSC Adv. 2022, 12, 19470–19484. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Structural formula of trimetazidine.
Figure 1. Structural formula of trimetazidine.
Molbank 2024 m1879 g001
Scheme 1. Synthesis of new sulfonamide derivatives of trimetazidine.
Scheme 1. Synthesis of new sulfonamide derivatives of trimetazidine.
Molbank 2024 m1879 sch001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ivanov, I.; Manolov, S.; Bojilov, D.; Dimitrova, D.; Nedialkov, P. Synthesis of Novel Sulfonamide Derivatives Featuring 1-(Methylsulfonyl)-4-(2,3,4-Trimethoxybenzyl)Piperazine Core Structures. Molbank 2024, 2024, M1879. https://doi.org/10.3390/M1879

AMA Style

Ivanov I, Manolov S, Bojilov D, Dimitrova D, Nedialkov P. Synthesis of Novel Sulfonamide Derivatives Featuring 1-(Methylsulfonyl)-4-(2,3,4-Trimethoxybenzyl)Piperazine Core Structures. Molbank. 2024; 2024(3):M1879. https://doi.org/10.3390/M1879

Chicago/Turabian Style

Ivanov, Iliyan, Stanimir Manolov, Dimitar Bojilov, Diyana Dimitrova, and Paraskev Nedialkov. 2024. "Synthesis of Novel Sulfonamide Derivatives Featuring 1-(Methylsulfonyl)-4-(2,3,4-Trimethoxybenzyl)Piperazine Core Structures" Molbank 2024, no. 3: M1879. https://doi.org/10.3390/M1879

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop